Ginkgo Bioworks Holdings (DNA) Receivables (2020 - 2026)

Ginkgo Bioworks Holdings' Receivables history runs 7 years deep, the most recent figure standing at $11.9 million for Q1 2026.

• Quarterly Receivables fell 54.92% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.9 million (down 54.92% YoY) and the FY2025 annual result came in at $38.5 million, up 224.13% from the prior year.
• Receivables was $11.9 million for Q1 2026 at Ginkgo Bioworks Holdings, down from $38.5 million in the prior quarter.
• Across five years, Receivables topped out at $178.1 million in Q2 2022 and bottomed at $899000.0 in Q2 2023.
• A 5-year average of $45.0 million and a median of $24.2 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables sank 99.5% — and 2024, when it surged 1134.93%.
• Ginkgo Bioworks Holdings' Receivables stood at $1.6 million in 2022, then surged by 548.27% to $10.1 million in 2023, then climbed by 11.88% to $11.3 million in 2024, then surged by 240.94% to $38.5 million in 2025, then sank by 69.23% to $11.9 million in 2026.
• Business Quant data shows DNA's Receivables at $11.9 million in Q1 2026, $38.5 million in Q4 2025, and $32.6 million in Q3 2025.